The Priority Review

Policy Brief

Dechra acquires biotechnology company Gallant Pet Inc

Dechra completed its acquisition of Gallant Pet Inc, a U.S.-based animal health biotechnology company that develops off-the-shelf mesenchymal stromal cell therapies for pets. The transaction terms are confidential and the first innovation from Gallant's pipeline is anticipated as early as 2027.

Primary source

Company press release (PR Newswire), November 17, 2026

Dechra acquires biotechnology company, Gallant Pet, Inc.

Read the source: Dechra acquires biotechnology company, Gallant Pet, Inc. prnewswire.com

Machine-summarized from the source above; not independently reported. How we use automation